Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients

Show full item record



Permalink

http://hdl.handle.net/10138/306647

Citation

Nurmi , A , Muranen , T A , Pelttari , L M , Kiiski , J I , Heikkinen , T , Lehto , S , Kallioniemi , A , Schleutker , J , Bützow , R , Blomqvist , C , Aittomäki , K & Nevanlinna , H 2019 , ' Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients ' , International Journal of Cancer , vol. 145 , no. 10 , pp. 2692-2700 . https://doi.org/10.1002/ijc.32309

Title: Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients
Author: Nurmi, Anna; Muranen, Taru A.; Pelttari, Liisa M.; Kiiski, Johanna I.; Heikkinen, Tuomas; Lehto, Sini; Kallioniemi, Anne; Schleutker, Johanna; Bützow, Ralf; Blomqvist, Carl; Aittomäki, Kristiina; Nevanlinna, Heli
Other contributor: University of Helsinki, HUS Gynecology and Obstetrics
University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Genome-Scale Biology (GSB) Research Program
University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, University Management
University of Helsinki, Department of Oncology
University of Helsinki, Research Programs Unit
University of Helsinki, HUS Gynecology and Obstetrics












Date: 2019-11-15
Language: eng
Number of pages: 9
Belongs to series: International Journal of Cancer
ISSN: 0020-7136
DOI: https://doi.org/10.1002/ijc.32309
URI: http://hdl.handle.net/10138/306647
Abstract: Mutations in BRCA1 and BRCA2 genes predispose to breast and ovarian cancer (BC/OC) with a high lifetime risk, whereas mutations in PALB2, CHEK2, ATM, FANCM, RAD51C and RAD51D genes cause a moderately elevated risk. In the Finnish population, recurrent mutations have been identified in all of these genes, the latest being CHEK2 c.319+2T>A and c.444+1G>A. By genotyping 3,156 cases and 2,089 controls, we estimated the frequencies of CHEK2 c.319+2T>A and c.444+1G>A in Finnish BC patients. CHEK2 c.319+2T>A was detected in 0.7% of the patients, and it was associated with a high risk of BC in the unselected patient group (OR = 5.40 [95% CI 1.58-18.45], p = 0.007) and similarly in the familial patient group. CHEK2 c.444+1G>A was identified in 0.1% of all patients. Additionally, we evaluated the combined prevalence of recurrent moderate-risk gene mutations in 2,487 BC patients, 556 OC patients and 261 BRCA1/2 carriers from 109 families. The overall frequency of the mutations was 13.3% in 1,141 BRCA1/2-negative familial BC patients, 7.5% in 1,727 unselected BC patients and 7.2% in 556 unselected OC patients. At least one moderate-risk gene mutation was found in 12.5% of BRCA1 families and 7.1% of BRCA1 index patients, as well as in 17.0% of BRCA2 families and 11.3% of BRCA2 index patients, and the mutations were associated with an additional risk in the BRCA1/2 index patients (OR = 2.63 [1.15-5.48], p = 0.011). These results support gene panel testing of even multiple members of BC families where several mutations may segregate in different individuals.
Subject: 3122 Cancers
breast cancer
ovarian cancer
moderate-risk gene
double heterozygote
CHEK2
BRCA2 MUTATIONS
FANCM
FAMILY-HISTORY
RAD51C
GENE
PREDISPOSITION
CONFER SUSCEPTIBILITY
ATM
C.5791C-GREATER-THAN-T
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Nurmi_et_al_201 ... al_Journal_of_Cancer_1.pdf 539.3Kb PDF View/Open
Nurmi_et_al_201 ... onal_Journal_of_Cancer.pdf 754.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record